BioAdvance

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia that specializes in developing gene therapies for cardiovascular diseases. Founded in 2013, Renovacor is focused on addressing dilated cardiomyopathy (DCM), a condition that affects over 3 million individuals in the United States. The company's lead program utilizes a recombinant adeno-associated virus (AAV) to create a gene therapy targeting patients with DCM caused by mutations in the Bcl2-associated athanogene 3 (BAG3) gene. This specific genetic mutation is estimated to affect around 35,000 individuals in the U.S. and a similar number in Europe, representing an orphan disease as defined by FDA guidelines. Patients with BAG3 mutations tend to be younger and experience a faster progression to advanced heart failure compared to those with ischemic heart disease. Currently, these patients receive standard heart failure treatments, but the five-year survival rate remains at only 50%. Renovacor aims to develop a BAG3 gene replacement therapy that could prevent disease progression in this vulnerable population.

Phrase Health, Inc., founded in 2018 and based in Philadelphia, Pennsylvania, offers software solutions tailored for the healthcare sector. The company's platform is designed to help hospitals monitor and analyze the information provided to doctors and nurses at the point of care. By facilitating workflow management, Phrase Health enables healthcare professionals to identify actionable insights and supports data-driven process improvements. The software aids in decision-making and enhances user interaction, allowing for better coordination of strategic initiatives within healthcare environments.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

CytoVas LLC develops informatics platform that provides information on novel cellular markers of disease progression and individual treatment response to clinicians and drug developers. The company's platforms include CLOUD CYTOMICS and CytoVas Vascular Health Profile. CLOUD CYTOMICS provides automated data collection, mining, and modeling solutions to clinical researchers. CytoVas Vascular Health Profile provides cytometric vascular health event detection test for clinical studies. The company was incorporated in 2010 and is headquartered in Philadelphia, Pennsylvania.

HueDx is a Rapid, Quantitative, Assay-based (RQA) test development and launch platform that eliminates the need to develop physical devices and software to launch an RQA product.

TalexMedical, LLC is a Philadelphia-based company that develops and manufactures a medical device designed to treat external ear deformities in newborns. Its primary product, Infantear, is a Class I medical device that offers a nonsurgical ear molding system. This system is applied in an outpatient setting, providing a cost-effective alternative to traditional surgical procedures. Infantear is customizable and made from soft materials, ensuring comfort for the patient. The treatment involves a straightforward two-week application during the first three weeks of life, which allows pediatricians to address ear anomalies without the need for referrals to specialists. Founded in 2015, TalexMedical aims to enhance healthcare outcomes by improving results, increasing patient satisfaction, and reducing costs.

Keriton LLC specializes in a pumped breast milk management system tailored for neonatal intensive care units (NICUs). Founded in 2016 and based in Philadelphia, Pennsylvania, the company addresses the challenges of breast milk management, which is often manual and error-prone. Its platform allows for real-time tracking of milk inventory, feeding orders, and provides notifications for expiry dates and misfeeds. Additionally, it enables nurses to share media with mothers and offers insights into lactating mothers' milk production patterns. By automating and validating the breast milk management process, Keriton significantly reduces the time nurses spend on these tasks, lowers the risk of errors, and creates an audit trail for compliance. The system aims to enhance the pumping experience for mothers, which is linked to better clinical outcomes for infants. Keriton's approach aligns with the goals of improving patient outcomes, reducing costs, and fostering better family engagement, presenting a potential return on investment for hospitals.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Bainbridge Health, Inc. is a Philadelphia-based company that develops a clinical intelligence and data analytics platform focused on improving medication safety in hospital systems. Founded in 2016, the company provides solutions specifically for medication safety leaders, including an infusion pump management software known as InfusionWare. This platform allows clinicians to manage infusion data centrally, enhancing patient safety by streamlining data handling and reducing the likelihood of medication errors. Bainbridge Health’s vendor-agnostic approach eliminates the need for cumbersome data management practices, enabling hospitals to mitigate risks associated with medication errors while also lowering avoidable costs.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Olive Devices LLC is a company based in Philadelphia, Pennsylvania, that develops innovative smart glasses aimed at enhancing communication for individuals who are deaf or hard of hearing, as well as those with attention deficit disorder, early onset Alzheimer’s, and other communication or memory challenges. The smart glasses feature real-time speech-to-text captions that display in front of the user's eyes, facilitating better understanding in various settings. Additionally, Olive Devices offers a mobile application that complements the smart glasses by syncing captions to the cloud, allowing users to organize and utilize the information for note-taking and studying. The application also includes features for converting notes into memory games, tracking progress from educators, and enabling interactions between students and teachers. Founded in 2015, Olive Devices serves a diverse clientele, including teachers, students, parents, audiologists, and optometrists.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Oncora Medical, Inc. is a digital health company that specializes in developing an analytics platform aimed at enhancing the capabilities of radiation oncologists in delivering care to cancer patients. Founded in 2014 and based in Philadelphia, Pennsylvania, Oncora offers tools that facilitate the extraction and integration of clinical data from various sources, including electronic medical records and treatment planning software. This platform enables physicians to leverage historical data and predictive analytics for personalized treatment recommendations. Additionally, Oncora's software incorporates machine learning algorithms to analyze patient data, providing insights into treatment outcomes and improving decision-making in radiation oncology.

Mebias Discovery, LLC discovers and progresses pathway selective GPCR drugs. It offers GPCR targets for neurodegenerative disorders, mood disorders, pain (non-opioid), cardiovascular, and immuno-oncology. The company was incorporated in 2015 and is based in Philadelphia, Pennsylvania.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Allevi develops tools for designing and engineering 3D tissues, specializing in desktop 3D bioprinters that create functional living tissues. The company's offerings include bioinks composed of collagen and hyaluronic acid, alongside a cloud-based platform called Bioprint Online, which allows users to design structures, define materials, and monitor the printing process. Allevi's products are utilized by researchers in tissue engineering, regenerative medicine, material science, and cell biology, as well as by industrial and pharmaceutical companies for drug testing and development. The company's bioinks are available for purchase online. Founded in 2014 and based in Philadelphia, Pennsylvania, Allevi was previously known as BioBots, Inc.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

TowerView helps the 1 in 3 Americans with a chronic illness manage multiple medications. TowerView’s patients receive pre-filled medication trays that fit into a connected pillbox like a K-Cup into a Keurig coffee machine. Their pillbox can sense when patients forget a dose and automatically sends a text or phone reminder. Unlike other smart pillboxes, they send patients pre-filled medication trays sourced from a pharmacy so patients never have to fill their own pillbox and they work directly with nurses​ to target outreach for non-adherent patients. TowerView is rolling out with Independence Blue Cross in January 2015 and are in advanced discussions with numerous other health plans.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

BioDetego is developing, VASPfore, a new biomarker test for selecting cancer treatment protocols. The VASP marker provides information that will direct chemotherapy to high risk patients who will likely benefit from treatment while preventing costly and harmful treatment of low risk patients. BioDetego predicts that the VASPfore will provide payors enormous savings (>$150MM/year) by reducing total treatment costs. The company is led by David Zuzga, Ph.D., Founder and CEO, a research scientist with expertise in cell and molecular biology at La Salle University & Giovanni M. Pitari, M.D., Ph.D. Founder and CSO, a physician and research scientist with expertise in Translational Oncology.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Microbiota is spun out from university of Pennsylvania, to develop a gut microbiome-based treatment for hyperammonemia.

Enzium, Inc. specializes in developing and marketing fluorescence-based reagents for the detection of protease activity. Founded in 2011 and based in Pittsburgh, Pennsylvania, the company offers a range of protease activity detection kits for use in diagnostic and life science applications, including assays for caspases, matrix metalloproteinases, and microbial proteases. Enzium's proprietary technology utilizes a modular approach, allowing for the quick and flexible assembly of assay reagents by interchanging protein modules, similar to building with Lego bricks. This innovation enables the integration of their reagent kits across various research, drug development, and diagnostic pipelines. The company serves a diverse client base, including pharmaceutical and biotechnology firms, contract research organizations, academic institutions, and government research entities.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Halo Labs (formerly Optofluidics) is a venture backed scientific instrumentation company that commercializes high throughput biopharmaceutical quality control tools using the latest optics, image processing and microfluidics. Our investors and development partners include BioAdvance, the National Science Foundation, the Defense Advanced Research Projects Agency, and the Ben Franklin Technology Partners. In 2012 Optofluidics was named Philadelphia Life Sciences startup of the year.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Temple University, founded in 1884 and located in Philadelphia, is one of the largest four-year institutions in the United States, offering a wide range of academic programs and research opportunities. The university provides over 300 degree programs at the bachelor's, master's, and doctoral levels, excelling in professional education fields such as medicine, law, dentistry, architecture, and pharmacy. In addition to its strong academic offerings, Temple is home to vibrant student life, featuring over 200 student organizations, a student newspaper, and various arts and entertainment activities. The university manages an endowment fund that supports its operations and aims to preserve the purchasing power of its financial resources. Temple University maintains selective admissions for both undergraduate and graduate programs and offers financial aid options, including loans, grants, and scholarships, to assist eligible students in funding their education.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Immunome is a biotechnology company based in Exton, Pennsylvania, founded in 2008. It focuses on immunotherapy and antigen discovery, utilizing a proprietary software platform that facilitates the simultaneous identification of novel antigens and the patient-derived antibodies that target them. The company's innovative approach aims to enhance the development of therapeutic solutions by leveraging the immune system's natural capabilities.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

NexusPharma Inc. is a drug discovery company based in Philadelphia, Pennsylvania, focused on developing innovative anti-cancer treatments. Established in 2004, the company specializes in creating and testing patient-derived xenograft models and cell lines, which are crucial for validating investigational drug candidates and identifying biomarkers for cancer. By employing small-molecule protein-protein interaction inhibitors, NexusPharma aims to modulate biological targets using non-cytotoxic mechanisms. Its multi-disciplinary approach combines medicinal chemistry, biology, and bioinformatics, enhancing the predictive value of its models for clinical outcomes. The company develops Patient Derived Tumor Models (PDX) across various cancer indications, including pancreatic, renal, esophageal, rectal, breast, and lung carcinomas. As of June 2019, NexusPharma operates as a subsidiary of Genesis Biotechnology Group, LLC.

Jenrin Discovery, Inc. is a pharmaceutical company based in Philadelphia, Pennsylvania, founded in 2004. The company specializes in developing small molecule drugs and therapeutics aimed at treating chronic diseases by targeting peripheral tissues. Its research encompasses a range of therapeutic areas, including diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), autoimmune and inflammatory disorders, as well as malaria. Through its innovative approach, Jenrin Discovery seeks to create peripherally selective agents that address these diverse health challenges.

InfraScan, Inc. is a medical device company that specializes in developing and distributing hand-held diagnostic devices for assessing head injuries and strokes using near-infrared (NIR) technology. Its primary product, the Infrascanner, allows healthcare professionals to detect intracranial bleeding in patients with head trauma, which is crucial for timely intervention. The device is applicable in various settings, including hospitals, military operations, remote screenings, sports medicine, pediatrics, and ambulance services. InfraScan was founded in 2004 and is headquartered in Philadelphia, Pennsylvania, where it also operates a research and development lab. The company markets its products through a network of distributors across North America, South America, Africa, Asia, the Middle East, and Europe.

To prevail over cancer, marshaling heart and mind in bold scientific discovery, pioneering prevention, and compassionate care.

Avid develops molecular imaging agents to aid medical management of chronic human diseases. They are located in Philadelphia, PA. Their mission is to develop new molecular imaging agents capable of changing the medical management of significant, chronic human diseases by identifying the first stages of pathological change, potentially assisting in earlier diagnosis, and better management and development of new therapies.

Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

LumenVu, Inc., a privately held, development stage company based in Philadelphia.

Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.

The Wistar Institute is the nation's first independent institution dedicated to medical research and training, having transitioned from an anatomical teaching museum to a prominent leader in basic biomedical research. Designated as a National Cancer Institute Cancer Center in basic research since 1972, Wistar focuses on immunology, infectious diseases, and vaccine research. The institute is known for its significant contributions to medical science, including the development of vaccines for rabies, rubella, and rotavirus, as well as the identification of genes linked to breast, lung, and prostate cancers. Additionally, Wistar has been instrumental in creating monoclonal antibodies and various important research technologies, fostering a collaborative environment to address critical challenges in the biomedical field.

Acuity Pharmaceuticals is a pharmaceutical company based in Philadelphia, Pennsylvania, established in 2007. It specializes in the treatment and prevention of ophthalmic diseases, particularly focusing on age-related macular degeneration (AMD) and diabetic retinopathy (DR). The company is developing small interfering RNA compounds aimed at addressing vision loss associated with these conditions. One of its key products, Cand5, is a clinical compound designed to inhibit vascular endothelial growth factor, thereby targeting adult vision loss. In June 2011, Acuity Pharmaceuticals was acquired by OPKO Health, enhancing its capabilities in the ophthalmic market.

PhenoTech, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, focused on the discovery, development, and commercialization of reagents for diagnostic use in blood banks. The company specializes in blood diagnostic reagents, including Nanoscale Emissive Antibody-complexes for pre-transfusion testing. In addition to diagnostics, PhenoTech develops therapeutic agents, such as human-like monoclonal antibodies for treating Idiopathic Thrombocytopenic Purpura, an autoimmune disorder related to blood disorders. The company also offers anti-platelet agents, specifically Infusable gpIIb/IIIa antagonists, which are utilized after acute myocardial infarction and during procedures like balloon angioplasty or stent placement to prevent cardiac ischemic complications. PhenoTech was incorporated in 2003.

Cira Discovery Sciences creates new advanced algorithmic methods for analyzing High Dimensional Biology. The increasing availability of high-quality data from "-omics" methodologies represents an opportunity to create value for Life Sciences enterprises.

Alteris Therapeutics, Inc. is focused on the discovery and development of therapeutics and vaccines targeting cancer, utilizing alternative gene splice forms. The company's lead compound, ALT-110, is a therapeutic vaccine designed to combat the splice variant growth factor EGFRvIII and is currently undergoing testing in a Phase I cancer trial. Alteris Therapeutics also operates a drug discovery program aimed at various tumors, including those found in breast, colon, lung, ovarian, and central nervous system cancers. Founded in 2002 and based in Philadelphia, Pennsylvania, the company emphasizes the importance of alternative splicing, which affects a significant percentage of human genes, in creating disease-specific drugs. By identifying novel splice forms and their expression patterns, Alteris aims to advance the field of spliceomics, which has the potential to uncover new therapeutic targets in a manner similar to genomics and proteomics. Alteris Therapeutics is a subsidiary of Celldex Therapeutics Inc.